Medication info
DuoWel A Tablet 80/5/20 Milligrams

DuoWel A Tablet 80/5/20 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›80mg / 1 tabletRosuvastatin Calcium›20.8mg / 1 tabletAmlodipine Besylate›6.935mg / 1 tablet
Manufacturer / importer
Yuhan Corporation Co., Ltd.
Appearance
Oval film-coated tablet in deep pink color
Packaging
30 tablets/box [6 tablets/PTP X 5]
Approval status
Active

MFDS item code 201804681 · Approved 2018.11.27 · Insurance code 642105340

Summary

Main use
Treats hypertension and dyslipidemia, inhibits the progression of atherosclerosis, and prevents cardiovascular disease
Who takes it
Adults
Adult dose
Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking a telmisartan/amlodipine combination and rosuvastatin as separate products, they may be switched to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dosage adjustment is necessary for patients with mild or moderate renal impairment. For patients with severe renal impairment, it is recommended to initiate treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of telmisartan should not exceed 40 mg. ◦ Elderly patients: In patients 75 years of age or older, amlodipine clearance is reduced; therefore, initiate treatment at a low dose and increase the dose gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin, and should continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 mg once daily; the dose may be adjusted to a maintenance dose if a greater reduction in LDL cholesterol is required. The maintenance dose is 10 mg once daily, which is sufficient for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased up to a maximum of 20 mg per day. 2. Elderly patients: No dosage adjustment is required. 3. Patients with renal impairment: No dosage adjustment is required for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients.

Ingredients

Manufacturer
Yuhan Corporation Co., Ltd.

Efficacy & effects

Treats hypertension and dyslipidemia, inhibits the progression of atherosclerosis, and prevents cardiovascular disease

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol
  • smoking
  • family history of early coronary artery disease.
View approved original text

This medication is used in patients with essential hypertension who have difficulty controlling blood pressure with monotherapy using telmisartan and amlodipine and who also need rosuvastatin. The telmisartan/amlodipine combination effectively lowers blood pressure and improves hypertension, while rosuvastatin calcium helps manage hypercholesterolemia and dyslipidemia resistant to dietary measures. Additionally, rosuvastatin is used to delay the progression of atherosclerosis and reduce the risk of cardiovascular diseases. In particular, it also reduces the risk of recurrence of stroke, myocardial infarction, and revascularization procedures in high-risk patients. This medication is suitable for patients who need simultaneous management of blood pressure and lipids and improves cardiovascular health.

How to take

Adult dose

Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking a telmisartan/amlodipine combination and rosuvastatin as separate products, they may be switched to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dosage adjustment is necessary for patients with mild or moderate renal impairment. For patients with severe renal impairment, it is recommended to initiate treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of telmisartan should not exceed 40 mg. ◦ Elderly patients: In patients 75 years of age or older, amlodipine clearance is reduced; therefore, initiate treatment at a low dose and increase the dose gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin, and should continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 mg once daily; the dose may be adjusted to a maintenance dose if a greater reduction in LDL cholesterol is required. The maintenance dose is 10 mg once daily, which is sufficient for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased up to a maximum of 20 mg per day. 2. Elderly patients: No dosage adjustment is required. 3. Patients with renal impairment: No dosage adjustment is required for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients.

Precautions

This drug may cause serious harm to the fetus or newborn if used by pregnant women, thus it should be discontinued immediately upon confirmation of pregnancy. Patients with allergies to the components of this drug or related medications, a history of angioedema, severely impaired liver or kidney function, specific heart diseases, as well as pregnant or nursing women should not take this medication. Patients with slightly impaired liver or kidney function, elderly patients, or those with high serum potassium levels should exercise increased caution when using this medication, and periodic monitoring should be conducted if necessary. This drug may cause muscle-related side effects such as muscle pain or weakness; therefore, if severe or persistent muscle pain occurs, consult a doctor immediately, especially for patients at high risk of muscle damage. During the use of this medication, dizziness, headache, indigestion, and edema may occur; if these symptoms are severe or persistent, inform healthcare personnel. This drug may affect liver function, hence regular liver function tests are recommended for patients with a history of liver disease or suspected liver dysfunction. Due to its blood pressure-lowering effects, patients with hypotension or cardiovascular diseases should carefully monitor blood pressure changes while using this drug. There may be interactions when taken with other medications, so if other medications are being used, it is essential to inform the physician or pharmacist. This drug can cause increased drug concentration in Asian patients, necessitating possible dose adjustments. While taking this medication, avoid strenuous exercise or activities that strain the muscles, and immediately consult a professional upon experiencing unusual symptoms.

Side effects

  • Viral upper respiratory tract infection
  • conjunctivitis
  • peripheral edema
  • chest discomfort
  • dizziness
  • abdominal pain
  • duodenitis
  • joint pain
  • disc protrusion
  • spinal canal stenosis
Show 121 more
  • tinnitus
  • increased ALT
  • increased AST
  • increased ALP
  • increased γ-GTP
  • chronic gastritis
  • hiatal hernia
  • hepatocellular carcinoma
  • cerebral infarction
  • congestive heart failure
  • musculoskeletal pain
  • neck pain
  • nasopharyngitis
  • upper abdominal discomfort
  • upper abdominal pain
  • positional dizziness
  • dysuria
  • rhinitis
  • discomfort in the oropharynx
  • pulmonary disease
  • unspecified bowel disease
  • benign gastric neoplasm
  • hemorrhoids
  • skeletal pain
  • osteoporosis
  • sensory loss
  • movement disorders
  • atherosclerosis
  • frequent urination
  • ear ringing
  • hearing loss
  • bad breath
  • fatty liver
  • influenza-like symptoms
  • indigestion
  • myalgia
  • urinary tract infection
  • headache
  • pain
  • fatigue
  • cough
  • hypertension
  • chest pain
  • nausea
  • erectile dysfunction
  • low back pain
  • muscle cramps
  • myalgia
  • bradycardia
  • eosinophilia
  • thrombocytopenia
  • increased uric acid
  • liver function abnormalities
  • liver disease
  • acute renal failure
  • kidney impairment
  • anemia
  • elevated CPK
  • anaphylactic reaction
  • tendon pain
  • vascular edema
  • erectile dysfunction
  • increased sweating
  • flushing
  • allergy
  • fever
  • leg pain
  • malaise
  • palpitations
  • dependent edema
  • angina
  • rapid pulse
  • leg edema
  • abnormal ECG
  • insomnia
  • drowsiness
  • migraine
  • dizziness
  • sensory abnormalities
  • involuntary muscle contractions
  • sensory loss
  • flatulence
  • constipation
  • gastritis
  • vomiting
  • dry mouth
  • hemorrhoids
  • gastroenteritis
  • enteritis
  • gastroesophageal reflux
  • toothache
  • nonspecific gastrointestinal disease
  • gout
  • hypercholesterolemia
  • diabetes
  • arthritis
  • joint pain
  • leg numbness
  • anxiety
  • depression
  • nervous irritability
  • infection
  • fungal infection
  • abscess
  • otitis media
  • asthma
  • bronchitis
  • rhinitis
  • dyspnea
  • nosebleed
  • dermatitis
  • rash
  • eczema
  • itching
  • frequent urination
  • cystitis
  • cerebrovascular disease
  • visual disturbances
  • conjunctivitis
  • ear ringing
  • ear pain

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a light-protected, sealed container. Additionally, it is recommended to store it at room temperature between 1 to 30 degrees Celsius. Proper storage ensures prolonged efficacy of the medication.

Appearance and packaging

Appearance

Oval film-coated tablet in deep pink color

Package unit

30 tablets/box [6 tablets/PTP X 5]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.